NCPC released its semi-annual performance report, with a net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%

According to the Zhitong Finance APP, North China Pharmaceutical (600812.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 5.275 billion yuan, a year-on-year increase of 0.84%; the net profit attributable to shareholders of the listed company was 123 million yuan, a year-on-year increase of 71.56%; the net profit excluding non-recurring gains and losses was 120 million yuan, a year-on-year increase of 120.69%; and the basic earnings per share were 0.072 yuan.

The increase in total profit, the increase in net profit attributable to shareholders of the listed company, and the increase in basic earnings per share, as well as the increase in diluted earnings per share, were mainly due to the company's further deepening of comprehensive budget control, implementation of lean management, and comprehensive quality and efficiency improvement measures, which reduced procurement costs and various expenses, thereby enhancing profitability. The increase in net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses, and the increase in basic earnings per share after deducting non-recurring gains and losses, were mainly due to the significant reduction in non-recurring gains and losses compared to the same period last year while the company's net profit increased. The decrease in net cash flow from operating activities was mainly due to the receipt of land compensation of 410 million yuan from the Shijiazhuang Land Reserve Center in the first half of 2024